GLYCOBIOLOGY MARKET ANALYSIS

Glycobiology is the study of the composition, biosynthesis, biology, and evolution of saccharides, which are found in abundance in nature and are also known as carbohydrates, sugar chains, or glycans. Glycobiology has broad application in various sectors of fundamental study, biomedicine, and biotechnology. Glycans are essential biomolecules, they can be considered as simple monosaccharides, but they can also form more complex structures such as natural glycoconjugates in which sugar moieties are attached to proteins or lipids.

Global glycobiology market is estimated to be valued at US$ 1,568.73 million in 2022 and is expected to exhibit a CAGR of 12.9% during the forecast period (2022-2030).

Figure 1. Global Glycobiology Market Share (%), by Product Type, 2022

To learn more about this report, request a free sample copy

Increasing prevalence of cancer is expected to drive growth of the glycobiology market.

Glycobiology systems and tools such as enzymes, instruments, reagents and kits among others can be used for discovering drug targets, biomarkers and designing immunotherapy for cancer. Thus, the increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, according to data provided by National Cancer Institute, there were reportedly 16.9 million cancer survivors as of January 2019 in the U.S. Moreover, according to the same source up to 2030, there are expected to be 22.2 million cancer survivors and it is expected that by 2040, there would be 16.4 million cancer-related deaths and 29.5 million new instances of cancer each year.

Figure 2. Global Glycobiology Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

Increasing launches of glycobiology products  by biopharmaceutical companies such as instruments, reagents & kits are expected to drive market growth during the forecast period.

The significance of glycan changes in healthy and pathological states is being investigated by scientists, who are also looking at tumor growth, viral capture, and medication discovery. Thus the increasing use of glycan instruments, reagents, and kits such as immunofluorescence kit for detection of glycan expression in tissue is expected to drive the market growth over the forecast period. For instance, in July, 2022, Vector Laboratories a company providing life science products, announced the launch of the product Glysite Scout Glycan Screening Kit. These immunofluorescence (IF) kits are fully integrated for detection of glycan expression in tissue sections and support profiling and characterization of complex glycans in biological systems. Glysite Scout Glycan Screening Kit enables researchers to understand the importance of glycomics in samples for post-translational protein modifications and association with disease biomarkers.

Global Glycobiology Market– Impact of Coronavirus (COVID-19) Pandemic

According to the World Health Organization (WHO), the first identifiable COVID-19 case was detected in Wuhan Province, China in December 2019, and a global emergency was declared on 30 January 2020.

The COVID-19 impact created opportunity in the field of glycobiology, owing to its application in research activities and production of antiviral vaccines. Glycans are involved in various initiation and regulatory processes in living cells. Coronaviruses are glycosylated enveloped viruses that can be used to produce antiviral vaccines against COVID-19 infection. Thus, the increasing demand for producing antiviral vaccines due to the COVID-19 pandemic can be expected to drive the glycobiology market growth.

 However, the COVID-19 pandemic and lockdown caused a disruption in supply chains and transportation of raw materials and drugs.

Global Glycobiology Market: Key Developments

In January, 2022, the Iceni Glycoscience, a company with expertise in glycoscience (carbohydrate chemistry and biology), launched a new in-house research and drug development program focused on glycoscience and glycoengineering.

In July, 2022, Ludger, a company conducting research and development in glyco technology, announced the pre-launch of three Lewis X glycan standards CN-A2G2F2-20U, CN-A2[3]G1F1-20U, CN-A2[3]G1-20U. Lewis X (Lex) is a fucosylated trisaccharide glycan epitope distributed in eukaryotes and certain bacteria. This carbohydrate epitope has been found to play a role in many physiological and pathological processes such as pathogenesis of diseases. Carbohydrate epitope is up regulated in various cancers such as pancreatic, breast, colon, and lung tumors, plays an important role in cell-cell interactions, and has been found in infectious bacteria such as Helicobacter pylori.

Global Glycobiology Market: Restraint

The major factor that hinders growth of the global glycobiology market includes inaccuracy in measuring total structure of  glycans  due to variability in susceptibility to hydrolysis of different bonds, variability in degradation of individual saccharides, or lack of specificity or sensitivity in the assay such as immunotherapy assay.

Key Players

Major players operating in the global glycobiology market include Tracxn Technologies Limited, Agilent Tecnologies, Inc, Blirt.eu, Takara Bio Inc., Bio-Techne, Bruker Corporation,Thermo Fisher Scientific Inc., Shimadzu Corporation , New England Biolabs., Waters.co., Merck KGaA , Palleon Pharmaceuticals ,Asparia Glycomics, RayBiotech Life, Inc.,  Z Biotech, LLC.,  Chemily Glycoscience,  Lectenz Bio, 2BScientific , and Glycodiag.